Start with the end in mind
Thursday 5th September, 9am-12pm
Babraham Research Campus, CB22 3AT
The Cambridge Building, King’s Hedges Room
A free event for all biotechnology companies in the Cambridge area
About the day
It is never too early to think about engaging with NICE. NICE Scientific Advice can help to shape clinical trial protocols and early modelling plans to ensure that evidence generation is targeted at an early to stage to providing the data required at the end of the process, when a technology is appraised by NICE or other HTA bodies.
If you are a biotech company thinking about selling to a larger pharmaceutical company or going to market alone, it is important that early clinical plans incorporate the needs of the final decision makers, as well as the regulatory bodies. In this masterclass run by NICE Scientific Advice, you can learn about how NICE makes decisions, the important considerations in clinical trial development for payers, and how companies can engage with NICE.
Agenda
How NICE makes decisions on new technologies
How NICE makes decisions on new technologies
Differences in requirements between regulators and payers
When and how companies should engage with NICE
The value of seeking NICE scientific advice on clinical development plans
NICE Office for Market Access
If you are interested in speaking with the NICE Scientific Advice team individually and in a confidential setting after the workshop, please let us know when you register.
For more information and to register a place, email scientificadvice@nice.org.uk
NICE SCIENTIFIC ADVICE
A fee based consultancy service to developers of pharmaceuticals, biopharmaceuticals, digital health technologies and diagnostics.
Our confidential advice helps the life sciences industry develop high quality evidence generation plans that capture what matters to patients and the healthcare system.